Company-wide revenue
Reported revenue in 2021 ¥50.01B Reported revenue in 2025 ¥43.58B
- growth amount
- −¥6.43B
- growth annualized
- -3.4%
- growth total
- -12.9%
Japanese company profile · 4671
FALCO HOLDINGS Co.,Ltd.
In its FY2025 public filing, FALCO HOLDINGS Co.,Ltd. reports Clinical testing, Pharmacy, ICT Business. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 株式会社ファルコホールディングス
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
FALCO HOLDINGS Co.,Ltd.'s largest reported business by revenue in FY2025 was Clinical testing.
The business with the highest reported segment profit in FY2025 was Clinical testing.
FY2025 · fiscal year ended March 2026 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Sales | Revenue share | Operating profit |
|---|---|---|---|
| Clinical testing | ¥26.66B ↗ | 61.2% | ¥1.82B ↗ |
| Pharmacy | ¥15.2B ↗ | 34.9% | ¥674M ↗ |
| ICT Business | ¥1.72B ↗ | 3.9% | ¥458M ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended March 2026. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- Clinical testing
- 臨床検査事業
- Pharmacy
- 調剤薬局事業
- ICT Business
- ICT事業
- Sales
- 売上高
- Operating profit
- 営業利益
Original Japanese label
- Clinical testing
- 臨床検査事業
- Pharmacy
- 調剤薬局事業
- ICT Business
- ICT事業
- Sales
- 売上高
- Operating profit
- 営業利益
Reported Sales by business over time
Reported Sales by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Clinical testing | ¥33.67B | ¥30.95B | ¥25.95B | ¥26.4B | ¥26.66B |
| Pharmacy | ¥16.35B | ¥15.97B | ¥15.99B | ¥15.46B | ¥15.2B |
| ICT Business | — | — | ¥1.07B | ¥1.45B | ¥1.72B |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
Business revenue growth
Pharmacy
Reported revenue in 2021 ¥16.35B Reported revenue in 2025 ¥15.2B
- growth amount
- −¥1.16B
- growth annualized
- -1.8%
- growth total
- -7.1%
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2025 · fiscal year ended March 2026
The source document may be in Japanese.
Filing ID: S100YIIX
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.